SEOUL, South Korea, May 13, 2026 — PharmaResearch Co., Ltd., the South Korean regenerative medicine company behind the REJURAN brand, has completed a five-market Western Europe roadshow for its PN-based skin booster REJURAN, as part of a phased expansion across the region.
The roadshow introduced healthcare practitioners (HCPs) to PharmaResearch's DNA Optimizing Technology (DOT™) and clinical applications of REJURAN. The company reported strong industry interest, with attendees raising detailed questions about product characteristics and practical uses.
The roadshow began with a Benelux symposium on April 22–23, followed by events in the United Kingdom on April 28 and Switzerland on April 30. The Benelux event, held near the Belgium-Netherlands border, gathered HCPs from both markets, while the UK event attracted medical professionals and industry stakeholders.
Global key opinion leaders (KOLs) led sessions presenting clinical results, treatment protocols, and real-world case examples. The sessions covered the full REJURAN portfolio: REJURAN for broader facial use, REJURAN I for thinner skin areas such as the eye area, and REJURAN S for wrinkle and scar-related applications.
PharmaResearch completed its first European market shipment in January and has been building a local distribution network. Following positive early feedback, the company is expanding product supply and increasing clinical education programs across the region.
Upcoming roadshow stops include Italy in May, Poland in June, and France in September. The company also plans to enter Germany and other European markets in the second half of 2026.
Vera Tual, Chief Customer Officer of VIVACY, PharmaResearch's European partner, said: "Although REJURAN is still in the early stages of its European launch, HCP's interest throughout the roadshow was strong. Attendees asked detailed questions about the product's characteristics and practical applications, suggesting that REJURAN's established reputation in Asia is helping build early momentum in Europe. The response also shows that REJURAN is quickly gaining attention among European HCPs as the new PN product for their aesthetic practices."
She added: "REJURAN complements VIVACY's existing aesthetics portfolio and gives us a valuable opportunity to engage with a wider network of medical professionals across Europe. We will continue to work closely with PharmaResearch to support the brand's successful rollout in each market."
A PharmaResearch representative said: "Interest in PN-based injectables is growing in Europe, but the market is still in its early stages. We see this as the right time to introduce REJURAN as a trusted PN-based skin booster backed by our DOT™ technology and clinical experience."
The representative continued: "REJURAN is gaining traction in Europe faster than we expected. We believe this reflects the pre-existing global presence of REJURAN in other markets, strength of our DOT™ technology, and the relevance of our product lineup for HCP. Based on the early response, we have raised our internal targets and will continue to expand distribution and education programs across Europe."
Source: Read the original report | Published: May 13, 2026